Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2894725 | 0.84 | PTGS2 (0.38) | LMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL2903058 | 0.75 | MEN1 (0.44) | LMNAHTTALDH1A1RAB9ANPC1 | |
| SCHEMBL2894972 | 0.75 | MEN1 (0.52) | LMNASMN1; SMN2HTTALDH1A1RAB9A | |
| SCHEMBL2897808 | 0.72 | HSPB1 (0.52) | LMNAHTTALDH1A1RAB9ANPC1 | |
| SCHEMBL2899323 | 0.72 | MAPT (0.39) | HTTALDH1A1MAPTMAPK1 | |
| SCHEMBL1712271 | 0.72 | MEN1 (0.50) | SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL2901814 | 0.72 | L3MBTL1 (0.44) | LMNASMN1; SMN2HTTALDH1A1RAB9A | |
| SCHEMBL315475 | 0.71 | ALDH1A1 (0.43) | SMN1; SMN2HTTALDH1A1RAB9ANPC1 | |
| SCHEMBL2901946 | 0.71 | RAB9A (0.54) | LMNASMN1; SMN2HTTALDH1A1RAB9A | |
| SCHEMBL2894886 | 0.71 | HRH3 (0.38) | HTTALDH1A1RAB9AMAPTKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
| EP-2236505-A1 | Acylated aminopyridines and pyridazines as insecticides | Bayer CropScience AG (DE) | 2010-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | AAAS, DDT, QDPR | LMNA 2262/4885SMN1; SMN2 2519/4885HTT 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.